About us
Read MoreGOHebei Saiyong new material Technology Co.,Ltd. is specialized in R&D, manufacturing and marketing APIS, pharmaceutical intermediates, we have two affiliated manufacturers. More than 70 percent products are exported to Europe, America, Japan and Southeast Asia.
Featured Products
The company has a complete quality management system, mature supporting automated production equipment.
New Arrvials
The company has a complete quality management system, mature supporting automated production equipment.
we advice to choose
a right decision
- our Team
- Company Culture
Our factory is located in ShiJiaZhuang City, an important chemical R & D and production base in China. In the past years, Hebei Saiyong New Material Technology Co.,Ltd. has established its professional team and advanced managements, excels in product sourcing and customized products.
Hebei Saiyong New Material Technology Co.,Ltd has built close collaborations with several well-known institutes in China. Development of new fine chemical, custom synthesis has been a significant part of our chemical's production.
we’ll ensure you always get
best results
-
ABOUT EXPORT For products exported we can offer COA Certificate and official PI. We have different couriers to different countries. clients throughout the world. -
24/7 SERVICE Products can be sent out in 72 hours after payment. Tracking number available, fixed service person are 7x24h for you to contact. -
HIGH QUALITY ISO/IEC 17025: 2017 CNAS laboratory accreditation. Products purity is test by our quality department strictly before sending. -
TRANSPORTATION Secure and discreet shipment. Various transportation methods for your choice, like DHL/UPS/TNT/FedEx/SF-express.
Inquiry for pricelist
For inquiries about our products or pricelist, please leave your email to us and we will be in touch within 24 hours.
submit nowlatest news & blogs
view more-
Undruggable: The Current State of Drugging Cancer Targets
The term ‘undruggable’ refers to proteins or targets that are challenging to target with conventional drugs. In recent years, researchers have made progress in developing drugs that can interact with these proteins, meaning terms such as ‘difficult to drug’ or ‘yet ...read more -
$60 billion market size! Market analysis of diabetes therapeutics
Multiple indications of the same drug seem to be another secret of success for pharmaceutical companies, such as semaglutide. According to the 2022 annual report of Novo Nordisk, the GLP-1 business of semaglutide had an annual revenue of 83.371 billion Danish kroner (about 11.812 billion ...read more -
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer APRIL 24, 2023
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for 177Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer BEDFORD, MA, and INDIANAPOLIS, IN, April 24, 2023 – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving ...read more
